{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:25:34Z","timestamp":1780514734842,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Denosumab has been widely utilized in the management of osteoporosis; however, thrombocytopenia as an adverse reaction associated with denosumab has been infrequently reported, and its underlying mechanism is not yet fully understood. We present a retrospective analysis of a rare case of suspected immune-mediated thrombocytopenia resembling immune thrombocytopenia (ITP) in a patient with primary osteoporosis following denosumab treatment, along with a comprehensive review of the relevant literature to investigate the potential mechanisms of denosumab-induced ITP-like thrombocytopenia. This case underscores the need for routine platelet monitoring during clinical use of denosumab and serves as a pharmacovigilance signal, providing a basis for future drug safety assessments.<\/jats:p>","DOI":"10.3389\/fphar.2026.1723393","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:39:06Z","timestamp":1777437546000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: A case of ITP-like thrombocytopenia induced by denosumab"],"prefix":"10.3389","volume":"17","author":[{"given":"Shijing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiahong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tmrv.2013.05.005","article-title":"Approach to the diagnosis and management of drug-induced immune thrombocytopenia","volume":"27","author":"Arnold","year":"2013","journal-title":"Transfus. Med. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3760\/cma.j.cn121090-20251031-00494","article-title":"Chinese guideline on the diagnosis and treatment of adult primary immune thrombocytopenia (2025)","volume":"46","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1182\/asheducation-2018.1.576","article-title":"Drug-associated thrombocytopenia","volume":"2018","author":"Bakchoul","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1182\/blood.v97.12.3846","article-title":"Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen","volume":"97","author":"Bougie","year":"2001","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1182\/blood-2006-12-063941","article-title":"Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen","volume":"109","author":"Bougie","year":"2007","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood.V92.7.2366","article-title":"Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes","volume":"92","author":"Burgess","year":"1998","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.crohns.2012.04.001","article-title":"Severe adalimumab-induced thrombocytopenia in a patient with crohn's disease","volume":"6","author":"Casanova","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","article-title":"Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases","volume":"11","author":"Delmas","year":"2008","journal-title":"J. Clin. Densitom."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.3390\/ijms241512150","article-title":"A novel mechanism for bone loss: platelet count negatively correlates with bone mineral density via megakaryocyte-derived RANKL","volume":"24","author":"Kikuchi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1046\/j.1365-2141.1997.1472960.x","article-title":"Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays","volume":"97","author":"Leach","year":"1997","journal-title":"Br. J. Haematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"Marini","year":"2022","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: a pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"B24","unstructured":"Causality Assessment: WHO-UMC [UPSALA Monitoring Centre] Causality Categories for ADR Reporting\n          \n          \n          2017"},{"key":"B25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in Adults: a living clinical guideline from the American college of physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2147\/DDDT.S148654","article-title":"Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"13","author":"Yanbeiy","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"B30","first-page":"102","article-title":"OPG\/RANKL\/RANK: a linkage between the skeletal and immune systems","volume":"42","author":"Zhang","year":"2020","journal-title":"Chin. J. Nat."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J. Clin. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1723393\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:39:38Z","timestamp":1777437578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1723393\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1723393"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1723393","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1723393"}}